ReShape Lifesciences Inc
NASDAQ:RSLS
Income Statement
Earnings Waterfall
ReShape Lifesciences Inc
Revenue
|
8.7m
USD
|
Cost of Revenue
|
-3.1m
USD
|
Gross Profit
|
5.5m
USD
|
Operating Expenses
|
-20.2m
USD
|
Operating Income
|
-14.6m
USD
|
Other Expenses
|
3.3m
USD
|
Net Income
|
-11.4m
USD
|
Income Statement
ReShape Lifesciences Inc
Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||
Revenue |
4
N/A
|
4
-8%
|
3
-6%
|
4
+12%
|
5
+31%
|
7
+41%
|
10
+42%
|
10
-1%
|
11
+8%
|
11
+2%
|
9
-15%
|
10
+5%
|
7
-25%
|
5
-37%
|
3
-28%
|
2
-30%
|
3
+14%
|
2
-11%
|
2
-31%
|
4
+153%
|
7
+70%
|
11
+54%
|
14
+29%
|
13
-6%
|
12
-5%
|
11
-7%
|
11
0%
|
11
-1%
|
10
-6%
|
10
-6%
|
9
-12%
|
|
Gross Profit | ||||||||||||||||||||||||||||||||
Cost of Revenue |
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(5)
|
(5)
|
(6)
|
(6)
|
(5)
|
(6)
|
(5)
|
(4)
|
(3)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(2)
|
(4)
|
(5)
|
(6)
|
(5)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(3)
|
|
Gross Profit |
1
N/A
|
1
-24%
|
1
-43%
|
1
+36%
|
2
+109%
|
3
+81%
|
5
+70%
|
5
-2%
|
5
+1%
|
5
+2%
|
4
-28%
|
4
-1%
|
2
-35%
|
1
-70%
|
0
-53%
|
0
-91%
|
1
+1 900%
|
1
+13%
|
1
-15%
|
3
+352%
|
4
+71%
|
7
+48%
|
8
+26%
|
7
-13%
|
7
-4%
|
7
-1%
|
7
-3%
|
7
N/A
|
6
-10%
|
5
-13%
|
6
+5%
|
|
Operating Income | ||||||||||||||||||||||||||||||||
Operating Expenses |
(17)
|
(18)
|
(20)
|
(25)
|
(29)
|
(35)
|
(39)
|
(44)
|
(46)
|
(43)
|
(41)
|
(37)
|
(32)
|
(28)
|
(24)
|
(20)
|
(17)
|
(15)
|
(11)
|
(11)
|
(13)
|
(29)
|
(36)
|
(71)
|
(76)
|
(35)
|
(34)
|
(51)
|
(25)
|
(23)
|
(20)
|
|
Selling, General & Administrative |
(5)
|
(7)
|
(10)
|
(15)
|
(19)
|
(24)
|
(29)
|
(33)
|
(34)
|
(32)
|
(30)
|
(26)
|
(23)
|
(20)
|
(17)
|
(14)
|
(12)
|
(11)
|
(9)
|
(9)
|
(12)
|
(27)
|
(33)
|
(38)
|
(42)
|
(33)
|
(31)
|
(29)
|
(23)
|
(21)
|
(18)
|
|
Research & Development |
(12)
|
(11)
|
(10)
|
(10)
|
(10)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(9)
|
(8)
|
(7)
|
(6)
|
(5)
|
(4)
|
(2)
|
(2)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(2)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(31)
|
(31)
|
0
|
0
|
(20)
|
0
|
0
|
0
|
|
Operating Income |
(16)
N/A
|
(17)
-7%
|
(20)
-17%
|
(24)
-22%
|
(27)
-15%
|
(32)
-17%
|
(34)
-7%
|
(39)
-13%
|
(41)
-5%
|
(38)
+6%
|
(37)
+3%
|
(33)
+11%
|
(30)
+10%
|
(27)
+10%
|
(23)
+14%
|
(20)
+14%
|
(16)
+18%
|
(14)
+13%
|
(11)
+26%
|
(8)
+25%
|
(9)
-11%
|
(22)
-152%
|
(27)
-22%
|
(64)
-134%
|
(69)
-9%
|
(29)
+59%
|
(27)
+5%
|
(44)
-62%
|
(19)
+56%
|
(17)
+9%
|
(15)
+16%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||
Interest Income Expense |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
3
|
3
|
4
|
4
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(3)
|
(2)
|
(2)
|
(33)
|
0
|
0
|
(38)
|
(19)
|
0
|
(19)
|
(13)
|
(1)
|
|
Total Other Income |
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(3)
|
(3)
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(16)
N/A
|
(18)
-11%
|
(20)
-15%
|
(25)
-20%
|
(28)
-15%
|
(32)
-14%
|
(35)
-8%
|
(39)
-13%
|
(41)
-5%
|
(39)
+6%
|
(37)
+4%
|
(34)
+10%
|
(31)
+9%
|
(28)
+10%
|
(24)
+14%
|
(21)
+13%
|
(18)
+12%
|
(16)
+12%
|
(12)
+23%
|
(12)
+3%
|
(12)
+3%
|
(28)
-139%
|
(63)
-128%
|
(67)
-5%
|
(72)
-8%
|
(67)
+7%
|
(47)
+31%
|
(41)
+12%
|
(35)
+14%
|
(26)
+26%
|
(11)
+57%
|
|
Net Income | ||||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
(0)
|
(0)
|
|
Income from Continuing Operations |
(16)
|
(18)
|
(20)
|
(25)
|
(28)
|
(32)
|
(35)
|
(39)
|
(41)
|
(39)
|
(37)
|
(34)
|
(31)
|
(28)
|
(24)
|
(21)
|
(18)
|
(16)
|
(12)
|
(12)
|
(12)
|
(28)
|
(63)
|
(66)
|
(72)
|
(66)
|
(46)
|
(41)
|
(35)
|
(26)
|
(11)
|
|
Net Income (Common) |
(16)
N/A
|
(18)
-11%
|
(20)
-15%
|
(25)
-20%
|
(28)
-15%
|
(32)
-14%
|
(35)
-8%
|
(39)
-13%
|
(41)
-5%
|
(39)
+6%
|
(37)
+4%
|
(34)
+10%
|
(31)
+9%
|
(28)
+10%
|
(24)
+14%
|
(21)
+13%
|
(18)
+12%
|
(16)
+12%
|
(12)
+23%
|
(12)
+3%
|
(12)
+2%
|
(28)
-138%
|
(63)
-127%
|
(66)
-5%
|
(72)
-8%
|
(66)
+8%
|
(46)
+30%
|
(41)
+11%
|
(35)
+15%
|
(26)
+25%
|
(11)
+57%
|
|
EPS (Diluted) |
-1 611
N/A
|
-1 781
-11%
|
-2 046.99
-15%
|
-2 463.99
-20%
|
-2 824
-15%
|
-3 215
-14%
|
-3 477
-8%
|
-3 915
-13%
|
-4 117
-5%
|
-3 875
+6%
|
-3 738
+4%
|
-1 677.49
+55%
|
-1 528.5
+9%
|
-688.25
+55%
|
-789.33
-15%
|
-412.99
+48%
|
-361.4
+12%
|
-318.39
+12%
|
-11 954.09
-3 655%
|
-149.37
+99%
|
-72.87
+51%
|
-115.83
-59%
|
-287.04
-148%
|
-179.43
+37%
|
-146.79
+18%
|
-147.6
-1%
|
-110.02
+25%
|
-23.91
+78%
|
-10.75
+55%
|
-7.62
+29%
|
-1.91
+75%
|